Affiliations 

  • 1 Department of Oral and Maxillofacial Pathology, Surendera Dental College and Research Institute, Sri Ganganagar, Rajasthan, India
  • 2 Faculty of Dentistry, Department of Conservative Dentistry and Endodontics, Melaka Manipal Medical College, Melaka, Malaysia
  • 3 Department of Periodontics, Rama Dental College, Kanpur, Uttar Pradesh, India
  • 4 Adesh Institute of Dental Sciences and Research, Bathinda, Punjab, India
  • 5 Department of Periodontology and Oral Implantology, Dasmesh Institute of Research and Dental Sciences, Faridkot, Punjab, India
J Indian Soc Periodontol, 2015 5 28;19(2):239-41.
PMID: 26015682 DOI: 10.4103/0972-124X.145837

Abstract

Gingival enlargement comprises any clinical condition in which an increase in the size of the gingiva is observed. It is a side effect associated with some distinct classes of drugs, such as anticonvulsants, immunosuppressant, and calcium channel blockers. Among calcium channel blockers, nifedipine causes gingival enlargement in about 10% of patients, whereas the incidence of amlodipine, a third-generation calcium channel blocker, induced gingival enlargement is very limited. Because the calcium antagonists, albeit to a variable degree, act as inhibitors of P-glycoprotein (P-gp), the gene product of multidrug resistance 1 (MDR1), and inflammation may modify P-gp expression. We hereby, report a case of amlodipine-induced gingival enlargement with MDR1 3435C/T polymorphism, associated with inflammatory changes due to plaque accumulation, in a 50-year-old hypertensive male patient. The genotype obtained for the polymorphism was a heteromutant genotype, thus supporting the contention that the MDR1 polymorphism may alter the inflammatory response to the drug.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.